Abstract:In real‐world clinical experience, anti‐PD1 inhibitor and D+T combination should be recommended for resected Stage III melanoma since they both improved RFS compared to only observation. However, dual targeted therapy of Dabrafenib plus Trametinib might be more optimal for BRAF mutant patients, since the relatively poor response to immunotherapy in Chinese population. Background BRAF V600 mutation is the most common oncogenic alternation in melanoma and is visible in around 50% of cutaneous and 10%–15% of acral or mucosal subtypes. Currently, immunotherapy with anti‐PD‐1 blockade and dual‐targeted therapy with Dabrafenib plus trametinib (D + T) target therapy have been approved as adjuvant therapies for Stage III melanoma with BRAF V600 mutation. According to their phase III clinical trials, 3‐year recurrence‐free survival (RFS) is around 60% for both types of treatment. However, early disease control was slightly more effective with targeted therapy than immunotherapy. With different drug approval deadlines in China, anti‐PD1 monotherapy, D + T combination, and Vemurafenib (V) monotherapy have all been used in real clinical practice as adjuvant settings for stage III BRAF‐mut melanoma in recent years. We conducted this retrospective study to evaluate the efficacy of different treatments in the Chinese melanoma population. Methods Patients who underwent radical surgery and were diagnosed as Stage III melanoma harboring BRAF V600 mutation by pathological report were retrospectively identified at Fudan University Shanghai Cancer Center from January 2017 to December 2021. Patients with mucosal melanoma, or with follow‐up of <6 months, or receiving other adjuvant treatment were excluded. Pearson's chi‐squared test or Fisher's exact test was performed for univariable analysis of the different adjuvant groups. Log‐rank analysis was used to identify prognostic factors for relapse‐free survival (RFS). Results Ninety‐three patients with resected stage III melanoma with BRAF V600E mutation were identified in our study, including 25 patients receiving adjuvant anti‐PD‐1 immunotherapy (PD‐1), 25 receiving adjuvant D + T, 23 receiving V, and 20 patients with observation‐only (OBS). There were no statistical differences between treatment groups in baseline characteristics including age, gender, subtypes, primary thickness, ulceration, and nodal involvement. Median relapse‐free survival (RFS) time was not reached in the D + T group, 15 months in the V group, 15 months in the PD‐1 group, and 10 months in the OBS group, respectively. Compared to OBS, all three other groups showed a tendency to benefit from RFS, while only D + T achieved a statistical difference (p = 0.002). However, compared to D + T, anti‐PD‐1 monotherapy also showed significantly worse relapse control (p = 0.032). Conclusions For Chinese stage III melanoma with BRAF mutation, both novel targeted therapy and immunotherapy showed potential benefits in relapse‐free survival compared to observation only. Dual‐targeted D + T therapy may still be the best choice for adjuvant therapy because anti‐PD‐1 monotherapy has failed to report equivalent efficacy in real‐world practice.

Preoperative Treatment for Marginally Resectable Metastatic Melanoma: A Single Center Experience in China.

A Phase 2 Clinical Trial of Neoadjuvant Anti-Pd-1 Ab (toripalimab) Plus Axitinib in Resectable Mucosal Melanoma.

Efficacy and surgical safety of sequential surgical resection after pembrolizumab plus chemotherapy for initial unresectable stage IIIB non-small cell lung cancer

Efficacy and Safety of Pembrolizumab Plus Chemotherapy and Sequential Surgical Resection in Initial Unresectable Stage IIIB NSCLC.

Comparative analysis of adjuvant therapy for stage III BRAF‐mut melanoma: A real‐world retrospective study from single center in China

Long‐term efficacy of neoadjuvant–adjuvant targeted therapy in borderline resectable stage IIIB–D and IV melanoma

Neoadjuvant Pembrolizumab and Lenvatinib in Resectable Mucosal Melanoma: NeoPlus Study Update.

796P Neoadjuvant Toripalimab Plus Axitinib in Patients (pts) with Resectable Mucosal Melanoma (mum): Updated Findings of a Single-Arm, Phase II Trial

Neoadjuvant Immunotherapy Followed by Surgery with Curative Intent in 35 Patients with Advanced NSCLC: the Retrospective Experiences of a Multidisciplinary Team.

Treatment of Stage III Resectable Melanoma—Adjuvant and Neoadjuvant Approaches

Efficacy and Safety of Combined Anti-Angiogenic Chemoradiotherapy with PD-1 Monoclonal Antibody in Advanced Melanoma: A Retrospective Study.

Neoadjuvant Therapy in Advanced Melanoma.

Endoscopic Surgery Combined Chemoradiotherapy and PD-1 Blockade in Patients with Sinonasal Mucosal Melanoma.

Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma

Efficacy and safety of neoadjuvant preoperative short-course radiation followed by envafolimab plus CAPEOX in microsatellite stable (MSS)/mismatch repair proficient (pMMR) locally advanced rectal cancer.

A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations

Efficacy of Adjuvant Programmed Cell Death 1 (PD-1) Monoclonal Antibody Immunotherapy in Chinese Patients with Resected Stage Ⅱ-Ⅲ Melanoma

NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.

Toripalimab (Anti-Pd-1) Plus Recombinant Human Endostatin As Adjuvant Therapy in Patients with Resected Stage III Melanoma: Interim Analysis of an Open-Label Phase II Trial.

Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma.

Perioperative therapy of melanoma: Adjuvant or neoadjuvant treatment